Insider · SEC Form 4 filer

David Goeddel

Companies

Where they file as an insider

Tenaya Therapeutics (TNYA) Director, 10% owner Latest filing Mar 5, 2025
NGM Biopharmaceuticals (NGM) Director, 10% owner Latest filing Apr 5, 2024

Track record

Did their buys beat the typical stock?

Open-market buys6
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check0

Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.

Tenaya Therapeutics (TNYA) Bought Mar 5, 2025 · $25M · 35.71M shares Beat typical Mar 31, 2025 $0.57 → Sep 30, 2025 $1.62 · +184.2% (typical stock +7.3%)
Tenaya Therapeutics (TNYA) Bought Feb 12, 2024 · $10M · 2.22M shares Behind typical Mar 31, 2024 $5.23 → Sep 30, 2024 $1.93 · −63.1% (typical stock +3.2%)
NGM Biopharmaceuticals (NGM) Bought Nov 15–16, 2023 · $18.4K · 26,811 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2023 and Jun 30, 2024.

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist